Aktienanalyse zu Biogen Inc. (BIIB)BIIBBiogen Inc.

Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Biogen Inc is a good buy right now, trading at $232.65 with a forward P/E of 13.95, suggesting strong earnings potential relative to its price. The recent upgrade by JPMorgan, raising the price target from $210 to $300, reflects confidence in its pipeline and potential catalysts, particularly the upcoming clinical data expected in 2027. However, the stock faces a risk with insider selling increasing by 864.10% over the last month, indicating potential concerns among insiders.

32 analysts cover BIIB: 21 rate it Buy, 11 Hold and 0 Sell. The average price target is 204.45.